Mission 03 · NAD+ / research guide
The number rose.
Then what?
NAD+ matters to cells. A higher blood reading still needs a health result beside it.
About 3 min · Study settings kept in view

The short version.
Human trials of oral NR and NMN raised blood NAD+. Some found specific functional changes. Lasting disease prevention and longer human life remain unproved.
- The substance
- NAD+ is a coenzyme
- The trials
- Oral NR & NMN
- The catch
- Blood isn't every tissue
Mission log / 01
First, NAD+ is not a peptide
NAD+ is a coenzyme: a helper molecule used by enzymes. It helps with energy-releasing reactions and is used in processes including DNA repair, as the review of NAD+ biology explains.
NR and NMN are precursors—materials the body can turn into NAD+. The human trials here gave those materials by mouth. A result for one precursor is not automatically a result for NAD+ itself, a different preparation, or an infusion.
Mission log / 02
A higher blood level is the clearest result
In an eight-week NR trial in healthy overweight adults, whole-blood NAD+ increased. There were no significant differences in adverse events from placebo over that short study.
That supports a narrow, useful conclusion about blood levels and short-term observations in that group. It does not show that the brain or muscle changed in the same way, or that people will avoid disease or live longer.
Mission log / 03
Some human outcomes did change
A 60-day NMN study in healthy middle-aged adults reported improvements in walking distance and quality-of-life scores as well as blood NAD+. It is worth noticing an outcome someone might feel, while keeping the short follow-up in view.
In a ten-week trial in prediabetic, postmenopausal women, NMN improved muscle insulin sensitivity: muscle responded better to the hormone that helps it take up glucose. Body composition and HbA1c, a longer-term blood-sugar measure, did not change.
One improvement can sit beside unchanged results. These participants also cannot stand in for everyone who feels tired or is getting older.
Mission log / 04
The replenishment idea still has gaps
The 2025 review of human precursor trials found limited efficacy and sparse tissue-specific data. Even the familiar claim that NAD+ falls with age rests on a limited number of consistent human studies.
The biology is a reason to ask better questions. It is not proof that raising a blood number slows aging. The useful next result would connect a defined preparation with a lasting health benefit in a defined group of people.
Next flight path Compare the experiments side by sideA blood test can show that something changed. The next question is whether life changed with it.
The Supernova takeaway